Literature DB >> 7705816

p53 gene analysis of ovarian borderline tumors and stage I carcinomas.

J Kupryjanczyk1, D A Bell, D Dimeo, R Beauchamp, A D Thor, D W Yandell.   

Abstract

Mutations of the p53 gene are common in human ovarian carcinomas; however, their role in the early development of ovarian cancer is unclear. Twelve ovarian borderline tumors (BTs; eight of them p53 immunopositive) and 10 stage I carcinomas (four of them p53 immunopositive) were studied for genetic alterations in the p53 gene. The study was based on single-strand conformation polymorphism (SSCP) analysis and DNA sequencing of exons 2 through 11 of the p53 gene using DNA preparations from microdissected tumors. Mutations were found in 40% of the carcinomas (including a borderline component adjacent to carcinoma in one lesion) but in none of the pure BTs. These findings suggest that p53 mutations may not be commonly associated with the borderline phenotype of ovarian epithelial tumors but may occur during malignant transformation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7705816     DOI: 10.1016/0046-8177(95)90138-8

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

Review 1.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes.

Authors:  Katherine Stemke-Hale; Kristy Shipman; Isidora Kitsou-Mylona; David G de Castro; Vicky Hird; Robert Brown; James Flanagan; Hani Gabra; Gordon B Mills; Roshan Agarwal; Mona El-Bahrawy
Journal:  Mod Pathol       Date:  2012-11-23       Impact factor: 7.842

3.  Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction.

Authors:  J Kupryjańczyk; A Dansonka-Mieszkowska; T Szymańska; G Karpińska; A Rembiszewska; M Rusin; R Konopiński; E Kraszewska; A Timorek; D W Yandell; J Stelmachów
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

Review 4.  The Putative Role of TP53 Alterations and p53 Expression in Borderline Ovarian Tumors - Correlation with Clinicopathological Features and Prognosis: A Mini-Review.

Authors:  Andrzej Semczuk; Marek Gogacz; Anna Semczuk-Sikora; Maciej Jóźwik; Tomasz Rechberger
Journal:  J Cancer       Date:  2017-08-22       Impact factor: 4.207

5.  TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study.

Authors:  Jolanta Kupryjanczyk; Ewa Kraszewska; Izabela Ziolkowska-Seta; Radoslaw Madry; Agnieszka Timorek; Janina Markowska; Jerzy Stelmachow; Mariusz Bidzinski
Journal:  BMC Cancer       Date:  2008-01-29       Impact factor: 4.430

6.  TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.

Authors:  Y Wang; A Helland; R Holm; H Skomedal; V M Abeler; H E Danielsen; C G Tropé; A-L Børresen-Dale; G B Kristensen
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.